Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naglazyme two-dose study in infants with MPS VI
2005-003512-30Phase 4Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Mar 2007
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of galsulfase in mucopolysaccharidosis type VI (2 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoints: Changes in dysmorphic features, Changes in skeletal dysplasia and 1 more. Started Mar 2007; status: completed.
02
Drugs
galsulfase
03
Conditions
mucopolysaccharidosis type VI
Beyond the preview
Go deeper on 2005-003512-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003512-30.